At the 61st ASH Annual Meeting & Exposition, Sabina Chiaretti, “Sapienza” University of Rome, discusses her presentation: Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. A Single Center Experience.
1. What are the limitations of current therapeutic options for patients with relapsed/refractory acute lymphoblastic leukemia (ALL)? (0:05)
2. What is the mechanism of action of blinatumomab? (0:54)
3. What were the major findings of your retrospective study? (1:46)
4. What did the study findings teach us about the safety profile of blinatumomab and how to manage toxicities? (2:58)
5. How are these findings likely to impact on clinical practice? (4:43)
Sabina Chiaretti has received consultancy fees from Amgen, Shire, Pfizer and incyte.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Leukaemia
Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
Robin Foà: Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]
Elias Jabbour, ASH 2021: Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (PACE and OPTIC Trials)
We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials. Questions 1. What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!